Jessica C. Hassel
German Cancer Research Center · 657 works · 56,825 citations · h-index 69
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial